RD&E for the three months ended March 31, 2012 increased by $0.3 million compared with the prior year period. The increase was primarily due to the increases in spending in our lithography product line. RD&E spending was relatively stable for both quarters at 10% and 9% of net revenues for fiscal 2012 and 2011, respectively.
RD&E for the nine months ended March 31, 2012 increased by $1.3 million compared with the prior year period. The increase was primarily due to spending in our lithography product line and EPO group. Overall, spending as a percentage of net revenues was relatively unchanged at 10% for the nine months ended March 31, 2012 and 2011.
Other income (expense) for the nine months ended March 31, 2011 included a gain on acquisition of $1.3 million. Other income (expense) for the three and nine months ended March 31, 2012 includes $0.1 million and $0.4 million, respectively, that was recorded as interest expense on the payment of the future consideration as part of the acquisition.
Income tax expense for the three and nine months ended March 31, 2012 and 2011 included income taxes in state and foreign jurisdictions. The effective tax rate is lower than the statutory United States (“U.S.”) rate due to no U.S. federal income tax expense for the three and nine months ended March 31, 2012 and 2011 as a result of having valuation allowances on net deferred tax assets, including net operating loss carry-forwards in the United States. Income tax expense for the nine months ended March 31, 2011 also included an income tax benefit of $0.7 million from an adjustment of valuation allowances on our net deferred tax assets associated with the Richmond asset acquisition.
In fiscal 2009, we established a valuation allowance against substantially all our net deferred tax assets based upon the consideration of all available evidence. As of March 31, 2012, we have concluded that we should continue to maintain valuation allowances on substantially all of our net deferred tax assets. In future periods, the valuation allowances could be reduced based upon sufficient evidence indicating that it is more likely than not that a portion of the net deferred tax assets will be realized.
TRANSACTIONS WITH STOCKHOLDER
Revenues from Canon Inc., a stockholder, and Canon Sales Co., Inc., a distributor of certain of our products in Japan and a subsidiary of Canon Inc. (collectively referred to as “Canon”), amounted to $5.0 million and $6.4 million (13% and 16% of net revenues, respectively) for the three months ended March 31, 2012 and 2011, respectively. For the nine months ended March 31, 2012 and 2011, sales to Canon amounted to $14.0 million and $13.4 million (11% and 12% of net revenue, respectively.) Selling prices of products sold to Canon are based, generally, on the terms customarily given to distributors. At March 31, 2012 and June 30, 2011, there were, in the aggregate, $1.3 million and $2.6 million, respectively, of trade accounts receivable from Canon.
LIQUIDITY AND CAPITAL RESOURCES
We assess our liquidity in terms of our ability to generate cash to fund our operating, investing and financing activities. Our principal source of liquidity is our cash reserves and operating cash flows. In addition to operating cash flows, other significant factors that affect our overall management of liquidity include: capital expenditures, customer credit requirements, investments in businesses and the availability of bank lines of credit.
At March 31, 2012, cash and cash equivalents were $89.3 million, an increase of $28.3 million from $61.0 million at June 30, 2011, of which $16.3 million is located in foreign jurisdictions subject to repatriation regulations. The cash balance in our money market account, that is invested primarily in U.S. government securities, was $19.9 million as of March 31, 2012. We do not believe there is any risk to liquidity in the money market account, nor are there currently any limits on redemptions.
Cash provided by operating activities from continuing operations for the nine months ended March 31, 2012 of $31.1 million was primarily due to net earnings and reductions in accounts receivable. Accounts receivable decreased $8.0 million from June 30, 2011 and $4.0 million from December 31, 2011. Days sales outstanding on accounts receivable decreased to 53 days at March 31, 2012 compared to 58 days at December 31, 2011 and 63 days at June 30, 2011 primarily due to collection activities, including a reduction of overdue balances and the application of progress payments.
Cash used for investing activities for the nine months ended March 31, 2012 of $1.6 million was related to the purchase of property, plant and equipment ($2.5 million), partially offset by the proceeds from the maturity and sale of marketable securities ($1.1 million, net).
Cash provided by financing activities in the nine months ended March 31, 2012 was $0.7 million. For the nine months ended March 31, 2012, there were $2.9 million in proceeds from stock option exercises, partially offset by dividend payments of $2.2 million to noncontrolling interests.
We currently have no lines of credit. In the future, if the need for debt or credit lines arises, there is no assurance that we would be able to secure such financing. We believe we have sufficient cash flows from operations and cash reserves to maintain adequate amounts of liquidity and to meet our future liquidity requirements for at least the next twelve months.
26
OFF-BALANCE SHEET ARRANGEMENTS
We have not created, and are not party to, any special-purpose or off-balance sheet entities for the purpose of raising capital, incurring debt, or operating parts of our business that are not consolidated into our financial statements. We have not guaranteed any obligations of a third party.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes in our quantitative and qualitative market risk disclosures during the three months ended March 31, 2012. Please refer to Item 7a., “Quantitative and Qualitative Disclosures about Market Risk,” of our Annual Report on Form 10-K for the year ended June 30, 2011, filed with the Securities and Exchange Commission (the “2011 Annual Report”) for a discussion of our exposure to market risk.
Item 4. Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an evaluation, as of the end of the period covered by this report, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). Based upon their evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures were effective.
There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred in our most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27
PART II - Other Information
Item 1A. Risk Factors
Part I, “Item 1A. Risk Factors” in our 2011 Annual Report includes a listing of risk factors that could materially affect our business, financial condition, or future results. There have been no material changes in our risk factors from those set forth in our 2011 Annual Report; however, the risks described in our 2011 Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information about our purchases during the quarter ended March 31, 2012, of equity securities that are registered by us pursuant to Section 12 of the Securities Exchange Act of 1934.
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Period | | Total number of shares purchased | | Average price paid per share | | Total number of shares purchased as part of publicly announced plans or programs (1) | | Approximate dollar value of shares that may yet be purchased under the plans or programs (in millions) | |
| |
| |
| |
| |
| |
|
January 1, 2012 - January 31, 2012 | | | 5,898 | | $ | 16.93 | | | — | | $ | 5.0 | |
February 1, 2012 - February 29, 2012 | | | — | | | n/a | | | — | | $ | 5.0 | |
March 1, 2012 - March 31, 2012 | | | — | | | n/a | | | — | | $ | 5.0 | |
| | |
| (1) | In August 2007, our Board of Directors authorized the repurchase of up to $25.0 million of our outstanding common stock. During the three months ended March 31, 2012, there were no repurchases of common stock in the open market. These historical share repurchases have been effected pursuant to plans in conformity with Rule 10b5-1 under the Securities Exchange Act of 1934. This rule allows public companies to adopt written, pre-arranged stock trading plans when they do not have material, non-public information in their possession. The adoption of this stock trading plan allows us to repurchase our shares during periods when we otherwise might be prevented from doing so under insider trading laws or because of self-imposed trading blackout periods. |
28
Item 6. Exhibits
| | |
(a) | Exhibits: |
| | |
| 31.1 | Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | |
| 31.2 | Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | |
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | |
| 32.2 | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | |
| 101.INS* XBRL Instance Document |
| | |
| 101.SCH* XBRL Taxonomy Extension |
| | |
| 101.CAL* XBRL Taxonomy Extension Calculation Linkbase |
| | |
| 101.DEF* XBRL Taxonomy Extension Definition Linkbase |
| | |
| 101.LAB* XBRL Taxonomy Extension Label Linkbase |
| | |
| 101.PRE* XBRL Taxonomy Extension Presentation Linkbase |
*Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
29
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | |
| Zygo Corporation | |
|
| |
| (Registrant) | |
| | |
| /s/ Chris L. Koliopoulos | |
|
| |
| Chris L. Koliopoulos |
| President and Chief Executive Officer |
| | |
| /s/ John P. Jordan | |
|
| |
| John P. Jordan | |
| Vice President, Chief Financial Officer and Treasurer |
Date: May 10, 2012
30
EXHIBIT INDEX
| | |
| 31.1 | Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | |
| 31.2 | Certification Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
| | |
| 32.1 | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | |
| 32.2 | Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| | |
| 101.INS* XBRL Instance Document |
| | |
| 101.SCH* XBRL Taxonomy Extension |
| | |
| 101.CAL* XBRL Taxonomy Extension Calculation Linkbase |
| | |
| 101.DEF* XBRL Taxonomy Extension Definition Linkbase |
| | |
| 101.LAB* XBRL Taxonomy Extension Label Linkbase |
| | |
| 101.PRE* XBRL Taxonomy Extension Presentation Linkbase |
| |
| *Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections. |